For cancer immunologists who have long envisioned a vaccine that would train the immune system to rid itself of cancer, Provenge, the first therapeutic cancer vaccine to receive FDA approval in 2011, is a milestone worth celebrating

In 2010 and 2011, the FDA approved two novel cancer immunotherapies, the first therapeutic cancer vaccine called Provenge (sipuleucel-T), and a monoclonal antibody called Yervoy (ipilimumab) for metastatic melanoma

New research teams funded in pancreatic cancer, glioblastoma

Dana-Farber/Harvard Cancer Center and the David H

Dana-Farber/Harvard Cancer Center has announced its first round of funding through the Men’s Collaborative to Cure Women’s Cancers, an unprecedented partnership providing a vehicle for men to support cutting edge research in breast and gynecologic cancers across the DF/HCC community

Conquering cancer is too daunting for any one discipline, approach, or individual

While John Blenis, PhD (HMS), a cell biologist and biochemist interested in cancer cell metabolism, works at the basic science level, he collaborates with pre-clinical researchers